Biothera Release: Imprime PGG in Combination With Monoclonal Antibody Therapy Achieves 64% Complete Response Rate in Chronic Lymphocytic Leukemia Patients
EAGAN, Minn.--(BUSINESS WIRE)--All subjects in a phase 1 study of high risk, chronic lymphocytic leukemia responded to the combination therapy of Imprime PGG®, alemtuzumab (Campath®) and rituximab (Rituxan®) with 64% achieving a complete response, according to data presented this past weekend at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, GA.